{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:50:39Z","timestamp":1782208239215,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03584-6","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:33:05Z","timestamp":1776483185000},"page":"2836-2851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations"],"prefix":"10.1007","volume":"43","author":[{"given":"Shannon L.","family":"Piche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5428-1691","authenticated-orcid":false,"given":"Michelle D.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubha","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda L.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunanda V.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"2","key":"3584_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1053\/j.gastro.2021.10.017","volume":"162","author":"AF Peery","year":"2022","unstructured":"Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021. Gastroenterology. 2022;162(2):621\u201344. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.017.","journal-title":"Gastroenterology"},{"key":"3584_CR2","unstructured":"U.S. Food and Drug Administration. Biosimilar Basics for Patients. FDA. Updated August 1, 2024. Accessed Aug 4, 2025. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilars-basics-patients"},{"key":"3584_CR3","unstructured":"Biologics Price Competition and Innovation Act of 2009, Approval Pathway for Biosimilar Biologic Products. 42 USC \u00a7262(k)(2)(A) (2010)."},{"key":"3584_CR4","unstructured":"U.S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. (2015). Accessed Aug 4, 2025. https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"3584_CR5","unstructured":"U.S. Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: guidance for industry. (2019). Accessed Aug 4, 2025. https:\/\/www.fda.gov\/media\/124907\/download"},{"issue":"18","key":"3584_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/ajhp\/zxad120","volume":"80","author":"S Cisek","year":"2023","unstructured":"Cisek S, Choi D, Stubbings J, Bhat S. Preparing for the market entry of adalimumab biosimilars in the US in 2023: a primer for specialty pharmacists. Am J Health Syst Pharm. 2023;80(18):1223\u201333. https:\/\/doi.org\/10.1093\/ajhp\/zxad120.","journal-title":"Am J Health Syst Pharm"},{"key":"3584_CR7","unstructured":"U.S. Food and Drug Administration. Purple book: database of licensed biological products. Updated 2025. Accessed Aug 4, 2025. https:\/\/purplebooksearch.fda.gov"},{"key":"3584_CR8","unstructured":"Inflectra. Package insert. Pfizer Laboratories Div Pfizer Inc; 2024."},{"issue":"5","key":"3584_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cgh.2018.08.064","volume":"17","author":"LE Raffals","year":"2019","unstructured":"Raffals LE, Nguyen GC, Rubin DT. Switching between biologics and biosimilars in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2019;17(5):818\u201323. https:\/\/doi.org\/10.1016\/j.cgh.2018.08.064.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3584_CR10","unstructured":"Crohn\u2019s & Colitis Foundation. Biosimilars position statement. 2023. Accessed Aug 4, 2025. https:\/\/www.crohnscolitisfoundation.org\/sites\/default\/files\/2023-04\/Biosimilars%20statement%20April%202023.pdf"},{"issue":"6","key":"3584_CR11","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"120","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2025;120(6):1225\u201364. https:\/\/doi.org\/10.14309\/ajg.0000000000003465.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"3584_CR12","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV, Limketkai BN, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167(7):1307\u201343. https:\/\/doi.org\/10.1053\/j.gastro.2024.10.001.","journal-title":"Gastroenterology"},{"issue":"7","key":"3584_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/14712598.2024.2378090","volume":"24","author":"GR Lichtenstein","year":"2024","unstructured":"Lichtenstein GR, Soonasra A, Latymer M, Singh S, Feagan BG. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease. Expert Opin Biol Ther. 2024;24(7):691\u2013708. https:\/\/doi.org\/10.1080\/14712598.2024.2378090.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"3584_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad018","volume":"5","author":"DK Choi","year":"2023","unstructured":"Choi DK, Rubin DT, Puangampai A, Lach M. Role and impact of a clinical pharmacy team at an inflammatory bowel disease center. Crohns Colitis 360. 2023;5(2):otad018. https:\/\/doi.org\/10.1093\/crocol\/otad018.","journal-title":"Crohns Colitis 360"},{"issue":"4","key":"3584_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.18553\/jmcp.2020.26.4.410","volume":"26","author":"S Bhat","year":"2020","unstructured":"Bhat S, Altajar S, Shankar D, et al. Process and clinical outcomes of a biosimilar adoption program with Infliximab-Dyyb. J Manag Care Spec Pharm. 2020;26(4):410\u20136. https:\/\/doi.org\/10.18553\/jmcp.2020.26.4.410.","journal-title":"J Manag Care Spec Pharm"},{"issue":"20","key":"3584_CR16","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1602773.","journal-title":"N Engl J Med"},{"issue":"13","key":"3584_CR17","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"3584_CR18","unstructured":"Ustekinumab (including biosimilars). Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http:\/\/online.lexi.com. Accessed Aug 21, 2025."},{"key":"3584_CR19","unstructured":"Stelara. Package insert. Janssen Biotech, Inc; 2025."},{"key":"3584_CR20","unstructured":"Wezlana. Package insert. Optum Health Solutions (Ireland) Limited; 2025."},{"key":"3584_CR21","unstructured":"Selarsdi. Package insert. Teva Pharmaceuticals USA, Inc; 2025."},{"key":"3584_CR22","unstructured":"Imuldosa. Package insert. Accord BioPharma Inc; 2025."},{"key":"3584_CR23","unstructured":"Pyzchiva. Package insert. Sandoz Inc; 2025."},{"key":"3584_CR24","unstructured":"Yesintek. Package insert. Biocon Biologics Inc; 2024"},{"key":"3584_CR25","unstructured":"Steqeyma. Package insert. Celltrion USA Inc; 2025."},{"key":"3584_CR26","unstructured":"Otulfi. Package insert. Fresenius Kabi USA, LLC; 2024."},{"key":"3584_CR27","unstructured":"Starjemza. Package insert. Bio-Thera Solutions, Ltd; 2025."},{"issue":"2","key":"3584_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/ueg2.12682","volume":"13","author":"F D'Amico","year":"2025","unstructured":"D\u2019Amico F, Bencardino S, Gon\u00e7alves A, et al. Unlocking hope: the future of ustekinumab biosimilars in Crohn\u2019s disease treatment. United Eur opean Gastroenterol J. 2025;13(2):186\u2013200. https:\/\/doi.org\/10.1002\/ueg2.12682.","journal-title":"United Eur opean Gastroenterol J"},{"issue":"5","key":"3584_CR29","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/bjd\/ljae402","volume":"192","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Papp K, Trivedi M, et al. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks. Br J Dermatol. 2025;192(5):826\u201336. https:\/\/doi.org\/10.1093\/bjd\/ljae402.","journal-title":"Br J Dermatol"},{"issue":"8","key":"3584_CR30","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14712598.2023.2235263","volume":"23","author":"SR Feldman","year":"2023","unstructured":"Feldman SR, Reznichenko N, Berti F, et al. Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Expert Opin Biol Ther. 2023;23(8):759\u201371. https:\/\/doi.org\/10.1080\/14712598.2023.2235263.","journal-title":"Expert Opin Biol Ther"},{"key":"3584_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jdin.2025.09.004","volume":"24","author":"K Vekovska","year":"2025","unstructured":"Vekovska K, Imko-Walczuk B, Tich\u00fd M, et al. A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. JAAD Int. 2025;24:147\u201365. https:\/\/doi.org\/10.1016\/j.jdin.2025.09.004. (Published 2025 Sep 30).","journal-title":"JAAD Int"},{"issue":"3","key":"3584_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2024.04.045","volume":"91","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Narbutt J, Girolomoni G, et al. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2024;91(3):440\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.045.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3584_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2436607","volume":"35","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Narbutt J, Girolomoni G, et al. Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52. J Dermatolog Treat. 2024;35(1):2436607. https:\/\/doi.org\/10.1080\/09546634.2024.2436607.","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"3584_CR34","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/14712598.2025.2538608","volume":"25","author":"JC Szepietowski","year":"2025","unstructured":"Szepietowski JC, Reich A, Feldman SR, et al. Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28\u2011week results of the randomized, double-blind, phase 3 STELLAR-2 study. Expert Opin Biol Ther. 2025;25(8):913\u201324. https:\/\/doi.org\/10.1080\/14712598.2025.2538608.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"3584_CR35","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/14712598.2025.2576506","volume":"25","author":"JC Szepietowski","year":"2025","unstructured":"Szepietowski JC, Reich A, Feldman SR, et al. Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the phase 3 STELLAR-2 trial. Expert Opin Biol Ther. 2025;25(10):1121\u201333. https:\/\/doi.org\/10.1080\/14712598.2025.2576506.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"3584_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","volume":"38","author":"KA Papp","year":"2024","unstructured":"Papp KA, Lebwohl MG, Tha\u00e7i D, et al. Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase III study. BioDrugs. 2024;38(1):121\u201331. https:\/\/doi.org\/10.1007\/s40259-023-00630-5.","journal-title":"BioDrugs"},{"issue":"5","key":"3584_CR37","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s12325-025-03138-2","volume":"42","author":"K Papp","year":"2025","unstructured":"Papp K, Balser S, Nopora K, Rewerski P, Freudensprung B, Trieb M. A randomised, double\u2011blind trial to compare the efficacy, safety, and immunogenicity of the biosimilar ustekinumab FYB202 with reference ustekinumab in patients with moderate\u2011to\u2011severe plaque psoriasis. Adv Ther. 2025;42(5):2135\u201349. https:\/\/doi.org\/10.1007\/s12325-025-03138-2.","journal-title":"Adv Ther"},{"issue":"4","key":"3584_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jaad.2024.10.104","volume":"92","author":"X Man","year":"2025","unstructured":"Man X, Zaharieva K, Pulka G, et al. A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2025;92(4):724\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.104.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3584_CR39","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.jaad.2025.08.005","volume":"93","author":"X Man","year":"2025","unstructured":"Man X, Zaharieva K, Pulka G, et al. A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: treatment period 2 results (post week 28 to week 52). J Am Acad Dermatol. 2025;93(6):1448\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.005.","journal-title":"J Am Acad Dermatol"},{"issue":"48","key":"3584_CR40","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i48.114355","volume":"31","author":"J Kritzinger","year":"2025","unstructured":"Kritzinger J, Candel I, Kotrri G, et al. Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol. 2025;31(48):114355. https:\/\/doi.org\/10.3748\/wjg.v31.i48.114355.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3584_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/MPG.0000000000003462","volume":"75","author":"L Yossef","year":"2022","unstructured":"Yossef L, Wright M, Benedict J, et al. Patient and caregivers\u2019 perspectives on biosimilar use in pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2022;75(1):59\u201363. https:\/\/doi.org\/10.1097\/MPG.0000000000003462.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"3584_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-11570-3","volume":"24","author":"KA Ryan","year":"2024","unstructured":"Ryan KA, Cohen-Mekelburg S, Baker JA, et al. Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease. BMC Health Serv Res. 2024;24(1):1209. https:\/\/doi.org\/10.1186\/s12913-024-11570-3. (Published 2024 Oct 9).","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"3584_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429","volume":"5","author":"K Feng","year":"2024","unstructured":"Feng K, Russo M, Maini L, Kesselheim AS, Rome BN. Patient out-of-pocket costs for biologic drugs after biosimilar competition. JAMA Health Forum. 2024;5(3):e235429. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.5429. (Published 2024 Mar 1).","journal-title":"JAMA Health Forum"},{"issue":"10","key":"3584_CR44","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.cgh.2019.11.059","volume":"18","author":"OJ Adedokun","year":"2020","unstructured":"Adedokun OJ, Xu Z, Marano C, et al. Ustekinumab pharmacokinetics and exposure response in a Phase 3 randomized trial of patients with Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020;18(10):2244-2255.e9. https:\/\/doi.org\/10.1016\/j.cgh.2019.11.059.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"3584_CR45","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","volume":"15","author":"R Battat","year":"2017","unstructured":"Battat R, Kopylov U, Bessissow T, et al. Association between Ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s Disease. Clin Gastroenterol Hepatol. 2017;15(9):1427\u201334. https:\/\/doi.org\/10.1016\/j.cgh.2017.03.032. (e2).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3584_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60020250","volume":"60","author":"K Dutt","year":"2024","unstructured":"Dutt K, Vasudevan A. Therapeutic drug monitoring for biologic and small-molecule therapies for inflammatory bowel disease. Medicina (Kaunas). 2024;60(2):250. https:\/\/doi.org\/10.3390\/medicina60020250. (Published 2024 Jan 31).","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"3584_CR47","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","volume":"116","author":"AS Cheifetz","year":"2021","unstructured":"Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in Inflammatory Bowel Disease. Am J Gastroenterol. 2021;116(10):2014\u201325. https:\/\/doi.org\/10.14309\/ajg.0000000000001396.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3584_CR48","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/ibd\/izad065","volume":"30","author":"A Vasudevan","year":"2024","unstructured":"Vasudevan A, Tharayil V, Raffals LH, et al. Systematic review and meta-analysis: the association between serum Ustekinumab trough concentrations and treatment response in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024;30(4):660\u201370. https:\/\/doi.org\/10.1093\/ibd\/izad065.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"3584_CR49","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/cpdd.1473","volume":"13","author":"S Balser","year":"2024","unstructured":"Balser S, Nopora K, K\u00f6rner J, Wedemeyer RS, Ansch\u00fctz M, Schug B. New Ustekinumab biosimilar candidate FYB202: pharmacokinetic equivalence demonstrated in a randomized, double-blind, parallel-group, single-dose trial in healthy subjects. Clin Pharmacol Drug Dev. 2024;13(12):1308\u201316. https:\/\/doi.org\/10.1002\/cpdd.1473.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"3584_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.dld.2023.06.022","volume":"56","author":"P Wetwittayakhlang","year":"2024","unstructured":"Wetwittayakhlang P, Karkout K, Wongcha-Um A, et al. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with Inflammatory Bowel Disease: a prospective observational study. Dig Liver Dis. 2024;56(1):35\u201342. https:\/\/doi.org\/10.1016\/j.dld.2023.06.022.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"3584_CR51","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40259-022-00548-4","volume":"36","author":"K Dutt","year":"2022","unstructured":"Dutt K, Srinivasan A, Van Langenberg D. The Nocebo effect in a non-medical switching program from originator to biosimilar Infliximab in Inflammatory Bowel Disease. BioDrugs. 2022;36(5):639\u201344. https:\/\/doi.org\/10.1007\/s40259-022-00548-4.","journal-title":"BioDrugs"},{"issue":"12","key":"3584_CR52","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000795","volume":"15","author":"MD Long","year":"2024","unstructured":"Long MD, Kane S, Beaulieu D, Abraham B, Zhang X, Mahadevan U. Use of biosimilars to infliximab during pregnancy in women with inflammatory bowel disease: results from the pregnancy in inflammatory bowel disease and neonatal outcomes study. Clin Transl Gastroenterol. 2024;15(12):e00795. https:\/\/doi.org\/10.14309\/ctg.0000000000000795. (Published 2024 Dec 1).","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"3584_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59030523","volume":"59","author":"V Richter","year":"2023","unstructured":"Richter V, Cohen DL, Bermont A, Shalem T, Broide E, Shirin H. The perception among Israeli gastroenterologists regarding treatment of patients with biosimilar medications. Medicina (Kaunas). 2023;59(3):523. https:\/\/doi.org\/10.3390\/medicina59030523. (Published 2023 Mar 7).","journal-title":"Medicina (Kaunas)"},{"issue":"11S","key":"3584_CR54","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cgh.2025.04.005","volume":"23","author":"U Mahadevan","year":"2025","unstructured":"Mahadevan U, Seow CH, Barnes EL, et al. Global consensus statement on the management of pregnancy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025;23(11S):S1\u201360. https:\/\/doi.org\/10.1016\/j.cgh.2025.04.005.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"3584_CR55","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel JF, et al. Risankizumab versus Ustekinumab for moderate-to-severe Crohn\u2019s Disease. N Engl J Med. 2024;391(3):213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2314585.","journal-title":"N Engl J Med"},{"issue":"6","key":"3584_CR56","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","volume":"162","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, D\u2019Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650-1664.e8. https:\/\/doi.org\/10.1053\/j.gastro.2022.01.047.","journal-title":"Gastroenterology"},{"issue":"2","key":"3584_CR57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","volume":"9","author":"S Danese","year":"2024","unstructured":"Danese S, Panaccione R, Feagan BG, et al. Efficacy and safety of 48 weeks of Guselkumab for patients with Crohn\u2019s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024;9(2):133\u201346. https:\/\/doi.org\/10.1016\/S2468-1253(23)00318-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"3584_CR58","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"120","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2025;120(6):1225\u201364. https:\/\/doi.org\/10.14309\/ajg.0000000000003465. (Published 2025 Jun 3).","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"3584_CR59","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1053\/j.gastro.2025.09.038","volume":"169","author":"FI Scott","year":"2025","unstructured":"Scott FI, Ananthakrishnan AN, Click B, et al. AGA living clinical practice guideline on the pharmacologic management of moderate-to-severe Crohn\u2019s Disease. Gastroenterology. 2025;169(7):1397\u2013448. https:\/\/doi.org\/10.1053\/j.gastro.2025.09.038.","journal-title":"Gastroenterology"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03584-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:22:02Z","timestamp":1782206522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03584-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3584"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03584-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shannon Piche has no conflicts. Michelle Becker has served as a consultant to Johnson and Johnson. Shubha Bhat has served as a consultant to Celltrion, Eli Lilly, and Johnson and Johnson. Linda Huang has no conflicts. Sunanda Kane has served as consultant to Boerhinger Ingelheim, Bristol Meyers Squibb, Fresenius Kabi, Janssen, Lilly, Takeda and serves as Section Editor for UptoDate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}